Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Weichenthal

Showing results (101-110 of 167) with videos related to

Pageof 17
Sort By:
American Journal of Human Genetics|August 5, 2014
Fine mapping major histocompatibility complex associations in psoriasis and its clinical subtypesYukinori Okada, Buhm Han, Lam C Tsoi, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|December 12, 2017
S2k-Leitlinie - Kutane Lymphome Update 2016 - Teil 1: Klassifikation und Diagnostik (ICD10 C82 - C86)Edgar Dippel, Chalid Assaf, Jürgen C Becker, et al.
Cancers|June 2, 2021
Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma-A Retrospective Multicenter ADOReg StudyHenner Stege, Maximilian Haist, Michael Schultheis, et al.
European Journal of Cancer (Oxford, England : 1990)|February 26, 2026
Treatment patterns in geriatric patients with melanoma and the effect of age on the efficacy of immunotherapy: Analysis from the real-world multicenter registry ADOREGKonstantinos Lallas, Lena Nanz, Selma Ugurel, et al.
European Journal of Cancer (Oxford, England : 1990)|December 22, 2021
TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapyCarl M Thielmann, Johanna Matull, Anne Zaremba, et al.
Nature Genetics|October 19, 2010
Genome-wide association analysis identifies three psoriasis susceptibility lociPhilip E Stuart, Rajan P Nair, Eva Ellinghaus, et al.
European Journal of Cancer (Oxford, England : 1990)|January 24, 2018
Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective studySara Valpione, Matteo S Carlino, Johanna Mangana, et al.
European Journal of Cancer (Oxford, England : 1990)|March 18, 2018
Corrigendum to "Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study*" [Eur J Cancer 91 (2018) 116-124]Sara Valpione, Matteo S Carlino, Johanna Mangana, et al.
European Journal of Cancer (Oxford, England : 1990)|February 11, 2023
Characterisation and outcome of RAC1 mutated melanomaGeorg C Lodde, Philipp Jansen, Rudolf Herbst, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 30, 2026
Role of comorbidities and medication on immunotherapy efficacy in cSCC: A DeCOG multicentre analysisGlenn Geidel, Sabrina Bänsch, Laura Adam, et al.
Pageof 17

Showing results (101-110 of 167) with videos related to

Sort By:
Pageof 17
American Journal of Human Genetics|August 5, 2014
Fine mapping major histocompatibility complex associations in psoriasis and its clinical subtypesYukinori Okada, Buhm Han, Lam C Tsoi, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|December 12, 2017
S2k-Leitlinie - Kutane Lymphome Update 2016 - Teil 1: Klassifikation und Diagnostik (ICD10 C82 - C86)Edgar Dippel, Chalid Assaf, Jürgen C Becker, et al.
Cancers|June 2, 2021
Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma-A Retrospective Multicenter ADOReg StudyHenner Stege, Maximilian Haist, Michael Schultheis, et al.
European Journal of Cancer (Oxford, England : 1990)|February 26, 2026
Treatment patterns in geriatric patients with melanoma and the effect of age on the efficacy of immunotherapy: Analysis from the real-world multicenter registry ADOREGKonstantinos Lallas, Lena Nanz, Selma Ugurel, et al.
European Journal of Cancer (Oxford, England : 1990)|December 22, 2021
TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapyCarl M Thielmann, Johanna Matull, Anne Zaremba, et al.
Nature Genetics|October 19, 2010
Genome-wide association analysis identifies three psoriasis susceptibility lociPhilip E Stuart, Rajan P Nair, Eva Ellinghaus, et al.
European Journal of Cancer (Oxford, England : 1990)|January 24, 2018
Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective studySara Valpione, Matteo S Carlino, Johanna Mangana, et al.
European Journal of Cancer (Oxford, England : 1990)|March 18, 2018
Corrigendum to "Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study*" [Eur J Cancer 91 (2018) 116-124]Sara Valpione, Matteo S Carlino, Johanna Mangana, et al.
European Journal of Cancer (Oxford, England : 1990)|February 11, 2023
Characterisation and outcome of RAC1 mutated melanomaGeorg C Lodde, Philipp Jansen, Rudolf Herbst, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 30, 2026
Role of comorbidities and medication on immunotherapy efficacy in cSCC: A DeCOG multicentre analysisGlenn Geidel, Sabrina Bänsch, Laura Adam, et al.
Pageof 17